市場調查報告書
商品編碼
1403460
2030 年水凝膠敷料市場預測:按產品、材料、應用、最終用戶和地區分類的全球分析Hydrogel Dressing Market Forecasts to 2030 - Global Analysis By Product, Material, Application, End User and By Geography |
根據Stratistics MRC預測,2023年全球水凝膠敷料市場規模將達4,625億美元,預計2030年將達到7,643億美元,預測期內複合年成長率為7.4%。
水凝膠敷料是一種高含水量的醫用材料,旨在促進創傷治療並保持濕潤的環境。水凝膠敷料具有多種優點,包括冷卻效果、緩解疼痛和防止傷口脫水。水凝膠敷料可有效治療多種類型的傷口,包括燒傷、潰瘍和擦傷。
根據國際糖尿病聯盟(IDF)統計,截至2020年2月,有4.63億人患有糖尿病。
人們普遍認知到水凝膠敷料可促進組織修復和細胞增殖的最佳條件,因此將其涵蓋標準創傷護理方案中。水凝膠敷料已透過包括網路和醫療保健專業人員在內的各種管道普及,以幫助改善個人的健康。此外,醫療保健提供者現在能夠就傷口管理做出更資訊的決定,並認知到保持濕潤癒合環境的重要性。
由於使用尖端材料和技術,開發含有新型添加劑和專用聚合物的複雜水凝膠配方需要很高的製造成本。此外,醫院、診所和醫療保健提供者在將水凝膠敷料涵蓋標準創傷護理方案時可能會面臨財務挑戰。這種經濟負擔可能會影響患者的依從性或有利於更經濟的創傷護理選擇,從而阻礙市場擴張。
科技進步有助於敷料有效地創造和維持創傷治療的最佳環境,最終加速復原過程。敷料配備感測器和指示器,可監測各種傷口參數,例如 pH 值、溫度和感染標記。包括奈米技術在內的材料科學和技術的不斷創新,導致了具有增強性能的高度複雜的水凝膠配方的開發,從而推動了市場的擴張。
缺乏認知可能導致創傷護理程序不當和關鍵醫療設備的利用不足。大部分醫療保健專業人員和患者可能不完全了解水凝膠敷料的用途和好處。此外,認知度低導致需求低,導致水凝膠敷料無法進入市場或容易融入常規創傷護理程序,阻礙了該市場的成長。
COVID-19 的爆發對水凝膠敷料市場產生了一些負面影響。供應鏈中斷和物流挑戰影響了包括水凝膠敷料在內的醫療產品的供應。製造和分銷的延遲以及對某些醫療保健產品的需求增加造成了不確定性。此外,醫院在管理非新冠患者方面面臨挑戰,影響了先進創傷護理解決方案的常規使用。大流行造成的景氣衰退導致醫療機構的預算緊張,從而縮小了市場規模。
預計結晶質水凝膠領域將佔據最大佔有率。結晶質水凝膠由高含水量的凝膠組成,沒有明確的形狀,使其成為多種傷口類型的通用解決方案。它易於塗抹和去除,其清涼和舒緩作用可減少患者換藥時的疼痛和不適。此外,這些敷料在維持濕潤的傷口環境方面表現出色,促進促進癒合的最佳條件,從而顯著推動該細分市場的成長。
腿部靜脈潰瘍部分預計將在預測期內實現最高的複合年成長率,因為它解決了與慢性靜脈功能不全相關的特定治療需求。該產品透過創造促進癒合過程的最佳濕潤環境,在這些潰瘍的治療中發揮重要作用,包括經常發生在下肢的血液循環受損而造成的傷口。該領域的成長是由於醫療保健專業人員意識到水凝膠敷料在治療腿部靜脈潰瘍方面的有效性,有助於改善患者的治療結果和生活品質,從而推動了這一領域的成長。
由於強大的醫療基礎設施、技術創新和先進創傷護理的積極方法,北美在預測期內佔據了最大的市場佔有率。在北美,我們透過治療糖尿病和肥胖等慢性疾病來關注患者的治療結果和護理品質。加拿大、墨西哥、美國和其他地方的研究表明,水凝膠配方的研究和開發仍在繼續,以確保這些敷料滿足醫療保健專業人員和患者不斷變化的需求。我們正在支持該地區的發展。
預計歐洲在預測期內的複合年成長率最高。研究和開發有助於水凝膠配方的不斷創新,提高其有效性並擴大其應用。歐洲法規結構保證醫療產品的安全性和有效性,並增強醫療保健專業人員和患者的信心。 3M 公司、強生服務公司、美敦力公司和全錄輝公司等主要企業公司在技術創新和實證醫學方面發揮重要作用,進一步推動了該地區的擴張。
According to Stratistics MRC, the Global Hydrogel Dressing Market is accounted for $462.5 billion in 2023 and is expected to reach $764.3 billion by 2030 growing at a CAGR of 7.4% during the forecast period. A hydrogel dressing is a medical material with a high water content designed to promote wound healing and maintain a moist environment. Hydrogel dressings provide several benefits, including cooling effects, pain relief, and preventing wound dehydration. They are effective in managing various types of wounds, such as burns, ulcers, and abrasions.
According to International Diabetes Federation (IDF), as of February 2020, 463 million people were calculated to be living with diabetes.
The awareness that hydrogel dressings promote optimal conditions for tissue repair and cell proliferation has led to their integration into standard wound care protocols. These are promoted through various channels, including the internet and healthcare professionals, and empower individuals to advocate for their well-being. Furthermore, healthcare providers are now better equipped to make informed decisions about wound management, recognizing the significance of maintaining a moist healing environment.
The development of complex hydrogel formulations, which include novel additives and specialized polymers, involves high production costs as they are made using cutting-edge materials and technologies. In addition, hospitals, clinics, and healthcare providers may face financial challenges when incorporating hydrogel dressings into their standard wound care protocols. This financial burden may influence patient compliance and preference for more economical wound care options, hampering this market expansion.
The technological enhancements contribute to the dressings' efficacy in creating and maintaining an optimal environment for wound healing, ultimately accelerating the recovery process. These are equipped with sensors or indicators that monitor various wound parameters, such as pH levels, temperature, and infection markers. Continuous innovation in materials science technologies such as nanotechnology has led to the development of highly sophisticated hydrogel formulations with enhanced properties, which are driving this market expansion.
A lack of awareness may result in inadequate wound care procedures and inadequate use of a significant medical tool. It's possible that a sizable percentage of medical professionals and patients are not fully aware of the uses and advantages of hydrogel dressings. Additionally, low awareness can lead to low demand, which prevents hydrogel dressings from entering the market and from being easily incorporated into regular wound care routines, which is hindering this market's growth.
The COVID-19 pandemic has had several negative impacts on the hydrogel dressing market. Supply chain disruptions and logistic challenges affected the availability of medical products, including hydrogel dressings. Manufacturing and distribution delays, as well as increased demand for certain healthcare products, contributed to uncertainties. In addition, hospitals faced challenges in managing non-COVID patients, impacting the regular utilization of advanced wound care solutions. The economic downturn associated with the pandemic resulted in budget constraints for healthcare facilities, thereby impeding this market size.
The amorphous hydrogel segment is estimated to hold the largest share. These are composed of a high-water-content gel without a defined shape and are versatile solutions for various wound types. This is often preferred for managing partial-thickness burns, abrasions, and donor sites due to its ease of application and gentle removal, which offer cooling and soothing effects, reducing pain and discomfort for patients during dressing changes. Furthermore, these dressings excel at maintaining a moist wound environment, promoting optimal conditions for accelerated healing, thereby significantly driving this segment's growth.
The venous leg ulcer segment is anticipated to have highest CAGR during the forecast period, due to its ability to address a specific therapeutic need associated with chronic venous insufficiency. This plays a major role in managing these ulcers by creating an optimally moist environment that facilitates the healing process, including wounds caused by impaired blood circulation, often occurring in the lower extremities. As healthcare professionals increasingly recognize the efficacy of hydrogel dressings in managing venous leg ulcers, it is contributing to improved outcomes and quality of life for patients, which is boosting this segment expansion.
North America commanded the largest market share during the extrapolated period owing to a robust healthcare infrastructure, technological innovation, and a proactive approach to advanced wound care. They focused on patient outcomes and quality of care by treating chronic conditions, including diabetes and obesity. Regions such as Canada, Mexico, and the United States lead to continuous research and development in hydrogel formulations, ensuring that these dressings meet the evolving needs of healthcare providers and patients, which is boosting this region's growth.
Europe is expected to witness highest CAGR over the projection period. Research and development contribute to the continuous innovation of hydrogel formulations, enhancing their effectiveness and expanding their applications. Regulatory frameworks in Europe ensure the safety and efficacy of medical products, instilling confidence in healthcare professionals and patients alike. Key players, including 3M Company, Johnson & Johnson Services, Inc., Medtronic plc, and Smith & Nephew plc, play a major role in contributing technological innovations and evidence-based medicine, which further propel this region's expansion.
Some of the key players in the Hydrogel Dressing Market include 3M Company, Axelgaard Manufacturing Co Ltd, Convatec Group plc, B Braun Melsungen AG (B. Braun Holding GmbH & Co. KG), Integra LifeSciences, Hollister Incorporated, Lohmann & Rauscher GmbH & Co. KG, McKesson Corporation, Medline Industries LP, Procyon Corporation, Smith & Nephew plcand Amerx health care corp.
In August 2023, 3M announced that it has reached an agreement with the court-appointed negotiating plaintiffs' counsel to resolve the Combat Arms Earplug litigation against Aearo Technologies (Aearo) and 3M.
In September 2023, Procyon Advisors LLC had acquired a new position in the shares of ON Semiconductor Corporation during the second quarter.
In July 2023, Convatec Group Plc announced its collaboration with Tandem Diabetes Care on a new five-inch infusion set for Tandem Mobi, the world's smallest durable automated insulin delivery system that has now been FDA 510(k) cleared3.